InvestSMART

HEMOSTEMIX INC (TSX: HEM) - Share Price

Current share price for HEM : $0.065 0.005 (7.14%)+

Currency: CAD ($)

Hemostemix Inc is a clinical-stage biotechnology company whose principal business is to develop, manufacture, and commercialize blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments. Its product ACP-01 is derived from a patient's own blood and evaluated in clinical research for ischemic conditions, including Cardiovascular Ischemia, Peripheral Arterial Disease (PAD) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It , Chronic Limb Threatening Ischemia (CLTI), and Vascular Dementia.

HEM General Information +

TSX Code HEM
Industry/Sector Biotechnology
Market Cap ($M) 13
HEM Share Price $0.065
Day High $0.065
Day Low $0.065
Last Close $0.070
HEM Share Price Movement $0.01 ( 7.14% )
Prices as at 16:40, 15 Aug 2026
+Security prices are at best end-of-day and are indicative only.

HEM Financial Summary

Operating Revenue Per Share Price to Operating revenue Price to free cash flow Earnings Yield PE Ratio Dividend Yield Forward Dividend Yield Forward Earnings Yield
n/a n/a -$2.06 n/a n/a n/a n/a

HEM Calendar of Events

Created Date Changed Date Event
14 April 2026 14 April 2026 Company Meeting

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.